Tamiflu 75mg & 30mg - LSJ
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- 75A50324F80002-LSJ
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 36F79723D0219-75A50324F80002 Federal contract award
- Awardee
- Genentech Usa, Inc.
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- South San Francisco, California 94080, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response published a Limited/Sole Source Justification Notice for the procurement of 9,850,000 units of FDA-approved Tamiflu (oseltamivir phosphate) capsules in 75mg and 30mg strengths with a minimum 10-year shelf life. The Tamiflu capsules will be used to supplement the Strategic National Stockpile. The contract was awarded on November 20, 2023 to an unknown vendor under Solicitation Number 75A50324F80002-LSJ, but the award amount is unknown. The rationale for the Limited/Sole Source Justification is not provided in the summary.
Notice text
FDA-approved Tamiflu (oseltamivir phosphate) with at least a 10-year shelf life; total quantity of 9,850,000, 75mg and 30mg capsules in 10-count blister packages to supplement the Strategic National Stockpile.
Awarded contract 36F79723D0219 to unknown vendor for unknown amount on 2023-11-20.
Files
| File | Type | Posted |
|---|---|---|
| Tamiflu_LSJ_Redacted.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Limited / Sole Source Justification | |
| Tamiflu 75mg & 30mg - Award Notice | Award Notice | |
| Limited Source Justification - Tamiflu 30mg & 75mg capsules | Limited / Sole Source Justification |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity